Business Wire

REPLY

29.7.2024 09:31:30 CEST | Business Wire | Press release

Share
REPLY: Open Reply Supports OBI in Further Development of the "heyOBI" App and Marketing Solution Landscape

Open Reply, specialising in digital products and services within the Reply Group, has helped the OBI Group, which operates across Europe, to transform its digital customer and advisory communications. A key component of this support was the co-development of the "heyOBI" app, an innovative platform designed to optimise the customer experience across multiple channels. Relevant and personalised content makes "heyOBI" a reliable companion for customers' individual “Do-it-yourself” (DIY) activities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729261687/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Open Reply has helped the OBI Group to transform its digital customer and advisory communications. A key component of this support was the co-development of the "heyOBI" app, an innovative platform designed to optimise the customer experience across multiple channels. (Graphic: Business Wire)

Open Reply was also involved in the development of OBI's marketing technology (MarTech) landscape. This includes replacing traditional paper inserts with advanced digital solutions, resulting in a more efficient and targeted customer approach. The creation of a central communication hub within this MarTech landscape enables cross-organisational and targeted communication with end customers. This hub connects all touchpoints in the “heyOBI” app with its comprehensive database, ensuring seamless data exchange between different departments and employees at OBI. It allows the company to personalise offers and advice to customers and provide a better customer journey.

Furthermore, new communication channels and platforms, such as a customer mailbox and new areas on the website, have been introduced to increase engagement and generate more customer contacts. These channels allow customers to contact OBI directly and be put in touch with the most appropriate expert from a pool of OBI employees. Store navigation tools and an integrated customer card with couponing functionality complete the shopping experience.

The "heyOBI" app has seen strong growth in recent years, reaching more than six million users, which speaks to the high level of acceptance of the service. This is also reflected in the app's consistently positive ratings of 4.6 out of 5 stars in the Apple App Store with over 90,000 reviews.

John Krieger, senior vice president digital customer platform at OBI, commented: "Our transformative approach aims to deliver a seamless, customer-centric home improvement experience. The integration of digital solutions, in-store tools and personalised communications reflects our commitment to meeting the evolving needs of DIY and garden enthusiasts. With Open Reply's support, we will be able to guide our customers through their entire DIY journey and establish ourselves as a pioneer in customer-centric service design."

Reply

Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Open Reply

Open Reply is a Reply Group company specialising in digital transformation, mobile solutions and networked platforms. We offer cross-sector consulting services, conception, creation as well as the development of solutions based on mobile technologies with the aim of sustainably strengthening the market position through a state-of-the-art digital experience. www.open.reply.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240729261687/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye